VYXEOS Drug Patent Profile

When do Vyxeos patents expire, and what generic alternatives are available?

Vyxeos is a drug marketed by Jazz Pharms Therap and is included in one NDA. There are eight patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-six countries.

The generic ingredient in VYXEOS is cytarabine; daunorubicin. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cytarabine; daunorubicin profile page.

DrugPatentWatch^® Generic Entry Outlook for Vyxeos

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 30, 2028. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VYXEOS

International Patents:	148
US Patents:	8
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	11
Clinical Trials:	48
Patent Applications:	386
Drug Prices:	Drug price information for VYXEOS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VYXEOS
What excipients (inactive ingredients) are in VYXEOS?	VYXEOS excipients list
DailyMed Link:	VYXEOS at DailyMed

See drug prices for VYXEOS

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VYXEOS

Constraining patent/regulatory exclusivity:

TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PEDIATRIC PATIENTS AGES 1 YEAR AND OLDER

NDA:

209401

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VYXEOS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	Phase 3
Eastern Cooperative Oncology Group	Phase 2
St. Jude Children's Research Hospital	Phase 2

See all VYXEOS clinical trials

Pharmacology for VYXEOS

Drug Class	Anthracycline Topoisomerase Inhibitor Nucleoside Metabolic Inhibitor
Mechanism of Action	Nucleic Acid Synthesis Inhibitors Topoisomerase Inhibitors

US Patents and Regulatory Information for VYXEOS

VYXEOS is protected by eight US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PEDIATRIC PATIENTS AGES 1 YEAR AND OLDER.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes	8,518,437		Y
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes	10,835,492*PED				Y
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes	8,022,279*PED				Y

Expired US Patents for VYXEOS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017	8,431,806
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017	8,518,437

EU/EMA Drug Approvals for VYXEOS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Jazz Pharmaceuticals Ireland Limited	Vyxeos liposomal (previously known as Vyxeos)	daunorubicin, cytarabine	EMEA/H/C/004282Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).	Authorised	no	no	yes	2018-08-23

International Patents for VYXEOS

See the table below for patents covering VYXEOS around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2012326370
Brazil	112014009305
Canada	2852777

Supplementary Protection Certificates for VYXEOS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1744764	122018000134	Germany		PRODUCT NAME: ZUSAMMENSETZUNG AUS DAUNORUBICIN UND CYTARABIN; REGISTRATION NO/DATE: EU/1/18/1308 20180823
1744764	300960	Netherlands		PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827
1744764	2018C/045	Belgium		PRODUCT NAME: VYXEOS (DAUNORUBICINE/CYTARABINE); AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180823

VYXEOS (liposomal daunorubicin/cytarabine) market dynamics and financial trajectory: exclusivity, competitive pressure, and revenue outlook

Last updated: July 28, 2026

VYXEOS (liposomal daunorubicin and cytarabine) is a niche oncology product with concentrated demand in acute myeloid leukemia (AML). Financial trajectory since launch has been shaped by (1) high patient eligibility constraints and site-of-care intensity, (2) competitive substitution pressure from other AML induction and consolidation regimens, and (3) payer and formulary management typical of high-cost specialty oncology drugs. The next phase of risk centers on formulary access, utilization management, and any biosimilar or generic pathway only to the extent regulators and IP allow for non-Liposome daunorubicin/cytarabine products to compete indirectly.

What is VYXEOS and where does it sell in AML?

Featured answer: VYXEOS is a liposomal fixed-dose combination of daunorubicin and cytarabine indicated for newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC) in adults, and for certain relapsed/refractory settings in specific label conditions (depending on regulatory updates). Commercial adoption is tied to treatment center adoption of liposomal induction schedules, clinical pathway fit, and hospital procurement workflows.

Which patient segments drive demand?

Demand is largely constrained by:

• Diagnosis mix: therapy-related AML and AML with AML-MRC represent a subset of total AML.
• Performance status and eligibility: intensive chemotherapy eligibility affects addressable volume.
• Time-on-therapy and cycle structure: fixed regimen timing drives administration capacity planning and adherence.
• Response and subsequent lines: VYXEOS use can be shaped by what happens before and after induction (transplant pathway vs alternative consolidation).

Where does adoption cluster?

Commercial use is concentrated among:

• Large academic centers and high-volume community oncology groups with experience in induction-consolidation protocols.
• Centers that can execute liposomal delivery schedules reliably and manage expected toxicity monitoring.

What drives VYXEOS market dynamics: pricing, access, and hospital buying behavior?

Featured answer: VYXEOS pricing power depends less on broad AML coverage and more on payer willingness to cover a high-cost, procedure-intensive regimen for specific AML subtypes, with hospital contracts and utilization management driving net price and persistence.

Payer and formulary dynamics that matter

• Specialty pharmacy vs buy-and-bill: VYXEOS is typically handled through specialty channels or hospital procurement frameworks. Net pricing is influenced by contracting and rebates.
• Utilization management: prior authorization and evidence requirements are common levers in specialty oncology.
• Clinical pathway control: formulary committees weight guideline alignment and evidence strength for t-AML/AML-MRC subsets.

Hospital economics and operational adoption

Key operational determinants:

• Infusion capacity and pharmacy preparation: liposome-based administration requires adherence to protocol and supportive care.
• Therapy planning: fixed schedule dosing supports coordinated procurement and inpatient/outpatient planning.
• Treatment center experience: centers with existing AML induction/consolidation processes adopt faster.

How does VYXEOS revenue evolve over time after launch?

Featured answer: VYXEOS revenue trajectory historically tracks adoption curves in eligible patient cohorts, with subsequent-year growth dependent on incremental formulary access and cohort expansion via physician familiarity and referral patterns, then maturity driven by stable AML incidence, competitive regimen availability, and payer tightening.

Typical post-launch trajectory pattern for niche specialty oncology

1. Early ramp: market education and guideline uptake.
2. Mid-cycle growth: expansion via payer coverage and center penetration.
3. Maturity: utilization stabilizes as access saturates; growth becomes sensitive to:
   • competitive substitution,
   • label expansions (if any),
   • and real-world adherence to treatment protocol.

What competitive pressure affects VYXEOS: which alternatives substitute for liposomal daunorubicin/cytarabine?

Featured answer: VYXEOS competes for induction and consolidation treatment slots in AML, facing substitution from other intensive chemotherapy regimens and product-level alternatives, even when those alternatives are not identical. Substitution risk is highest where payers or institutions perceive similar outcomes or lower operational burden.

Competitive regimen categories

• Standard “3+7” intensive chemotherapy-like alternatives (varied daunorubicin/cytarabine schedules)
• Other liposomal or fixed combination chemotherapies if available in the relevant AML segments
• Targeted or immunotherapy additions in AML treatment pathways where the clinical decision framework allows modification

Why substitution can reduce VYXEOS utilization even without direct equivalence

• Protocol rigidity: once a center standardizes on another regimen, switching has operational and inertia costs.
• Payer leverage: coverage decisions can tilt toward regimens perceived as lower-cost or easier to administer.
• Patient fit: toxicity profiles and eligibility criteria can shift physician preference.

What is the IP and exclusivity timeline relevant to VYXEOS commercialization?

Featured answer: VYXEOS remains protected by a combination of formulation, composition, method-of-use, and formulation-specific patents, plus exclusivity tied to regulatory approvals. These protections delay direct generic or direct “same-drug” biosimilar-style entry, but do not block substitution by other AML treatments.

How exclusivity affects market dynamics

• No direct generic pressure: the largest near-term threat typically comes from therapeutic substitution rather than copying.
• Long-tail patent and formulation barriers: even if composition patents expire, formulation manufacturing and specific process claims can keep generic entry delayed or non-commercially viable.

What is the Orange Book status of VYXEOS and what does it imply for generic entry?

Featured answer: The Orange Book listing indicates which patents are listed for FDA-approved drugs and which exclusivity periods apply. For VYXEOS, generic entry risk is primarily delayed by listed patents tied to formulation and use; any Paragraph IV challenge would be constrained by the remaining patent term coverage.

Paragraph IV challenge risk: what matters

For high-cost, niche specialty oncology products:

• Paragraph IV filings are often timed when patent cliffs approach.
• Even after filing, settlements can result in delayed launch or “at-risk” entry limitations if patent stays or injunction threats are credible.

How strong is the patent estate for VYXEOS and what does that mean for pricing power?

Featured answer: VYXEOS pricing power is supported by a multi-layer patent estate that blocks direct generic replacement in the near-to-medium term, allowing sustained premium economics as long as clinical positioning remains defensible.

Patent estate implications for business

• Premium persistence: lack of direct generic competition sustains pricing discipline and reduces volume substitution toward identical products.
• Risk shifts to contract renegotiation: the most frequent commercial erosion tends to come from payer contracting rather than direct market copycat entry.

How do financials typically look for VYXEOS: what metrics track the trajectory?

Featured answer: The financial trajectory of VYXEOS is best tracked by net sales, growth rate vs the prior period, gross-to-net movement (rebates/contracting), prescription growth as a proxy for utilization, and operating margin contribution as a function of launch, marketing, and manufacturing scale-up.

Key KPI set for financial monitoring

• Net sales trend (quarterly and trailing twelve months)
• Gross-to-net ratio (rebates, discounts, patient assistance programs)
• Patient and prescription counts by quarter (where available in investor disclosures and specialty analytics)
• Acquisition cost structure and manufacturing throughput drivers
• Share of eligible AML patients treated in the specific indicated subgroup

What is VYXEOS’s revenue exposure versus the broader AML market?

Featured answer: VYXEOS revenue exposure is concentrated in a narrower subset of AML than broader “all-comers” induction products, reducing total market ceiling but strengthening defensibility when payer and physician adoption favor the indicated subgroups.

Why narrow indication reduces total TAM but raises adoption leverage

• Smaller patient pool caps maximum possible sales.
• Within the eligible segment, adoption can be highly sticky once centers standardize regimens and build outcomes experience.

What scenarios could change VYXEOS’s financial trajectory?

Featured answer: The trajectory is sensitive to three levers: formulary coverage and net price, center-of-care adoption dynamics, and competitive protocol substitution. Any regulatory or label expansion can shift the addressable cohort.

Downside scenarios

• Tightened payer criteria reducing eligible utilization
• Increased preference for competing regimens due to emerging protocols
• Manufacturing supply constraints or quality interruptions (where relevant)
• Expanded competition in liposomal or fixed-combination chemotherapy choices

Upside scenarios

• Broader guideline inclusion or expanded label indications within AML subgroups
• Improved persistence through optimized sequencing and reduced discontinuation
• Strengthened contracting that improves net price stability

Key Takeaways

• VYXEOS market dynamics are driven by niche AML segment focus (t-AML and AML-MRC) rather than broad AML coverage, making payer access and physician pathway fit the dominant commercial variables.
• Financial trajectory depends on center adoption and persistence, with growth typically flattening into maturity once formulary and referral patterns saturate.
• Near-term direct generic risk is constrained by formulation and use patent layers; competitive substitution from other AML regimens is the main utilization threat.
• The most material revenue levers are net price (gross-to-net) and eligible patient utilization, not generic entry alone.

FAQs

What are the main AML regimens that compete with VYXEOS for induction and consolidation?

VYXEOS competes for treatment slots in t-AML and AML-MRC using intensive chemotherapy alternatives and evolving AML combination pathways where protocol flexibility allows substitution.

Does VYXEOS face direct generic competition in the US?

Direct generic entry is generally delayed by listed patents and regulatory protections, so commercial erosion is more commonly driven by therapeutic substitution and payer contracting than by identical generic replacement.

What factors most influence VYXEOS net price?

Contracting terms, rebates/discounts, and utilization management (prior authorization criteria and coverage rules) drive gross-to-net and realized revenue.

How do treatment center adoption patterns affect VYXEOS growth?

Adoption is faster in centers with established AML induction and consolidation workflows that can reliably execute liposomal dosing schedules and supportive care protocols.

When would generic entry risk rise for VYXEOS based on patents?

Generic entry risk rises around relevant patent expiration cliffs tied to formulation/composition and method-of-use listings in the FDA Orange Book, with Paragraph IV challenges typically timed to remaining patent term.

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-28).
2. FDA label for VYXEOS (liposomal daunorubicin and cytarabine). (Accessed 2026-07-28).

DrugChatter Q&A for VYXEOS

What is intellectual property protection of vyxeos?
Vyxeos patent celator pharms chinese?
Vyxeos patent chinese pharmaceutical?